AOD-9604 peptide for sale: what to know before you buy

Last updated 2026-07-25

What is AOD-9604, and why is it sold as a fat-loss peptide?

AOD-9604 is a fragment of human growth hormone, specifically the region researchers thought was responsible for hGH's fat-metabolizing effect without the growth-promoting or blood-sugar side effects of full-length hGH. The idea was clean on paper: keep the lipolytic (fat-burning) piece, drop the rest. That rationale is real and it's the reason the compound got as far as human trials in the first place. A 2004 review in Current Opinion in Investigational Drugs covered AOD-9604's proposed metabolic mechanism as an anti-obesity candidate, tracking it as one of several hGH-fragment approaches being tested at the time ^[1]. A 2006 follow-up survey of obesity drugs in clinical development placed AOD-9604 among a crowded field of candidates, most of which never reached market ^[2]. None of that means the fragment strategy panned out in people. It means it was a reasonable hypothesis that got tested. Those are different things, and the distinction matters a lot once you're looking at a vial and a price tag. For the deeper mechanism discussion, see our AOD 9604 peptide overview.

Did AOD-9604 actually work in human obesity trials?

This is the question that should decide whether you buy it, and the honest answer is: not clearly. AOD-9604 went through human obesity trials sponsored by Metabolic Pharmaceuticals in the 2000s, and while some weight loss was reported in treated groups, it did not separate convincingly from placebo across the program. The published trial-tracking literature from that era, the 'Gateways to clinical trials' series in Methods and Findings in Experimental and Clinical Pharmacology, logged AOD-9604 moving through Phase II obesity trials in 2003 and into further clinical stages by 2005, alongside dozens of other compounds in development at the time ^[3][4][5]. These are trial registries and pipeline summaries rather than efficacy reports, but they confirm the compound reached human testing and stalled there rather than progressing to approval. No AOD-9604 product appears in the FDA's Drugs@FDA database, which lists every approved drug product in the United States ^[6]. That absence is the single fact that matters most if you're deciding whether to spend money on this peptide. Nearly two decades after those obesity trials began, AOD-9604 has not become an approved treatment for obesity, weight management, or anything else. Compare that against tesamorelin, which is FDA-approved for HIV-associated lipodystrophy and has a real Drugs@FDA listing. If you want the head-to-head on trial quality, read our AOD 9604 vs tesamorelin comparison before you buy anything.

Is AOD-9604 legal to buy and sell in the US?

AOD-9604 is not FDA-approved for any human use, and that status shapes everything about how it's legally sold. It shows up online labeled 'research use only,' which is a legal category, not a marketing choice. Under 21 CFR 201.128, a product's intended use is judged by how it's labeled, advertised, and represented, more than by what's printed on the vial ^[7]. A seller can't dodge drug regulation just by writing 'not for human consumption' if the marketing around it (dosing charts, fat-loss testimonials, bodybuilding forum tie-ins) tells a different story. AOD-9604 is also not on either FDA bulk drug substances list that allows compounding pharmacies to legally prepare it for patient use. The 503A list (21 CFR 216.23) covers substances compounding pharmacies can use under Section 503A of the FD&C Act, and the 503B list (21 CFR 216.24) covers outsourcing facilities ^[8][9]. FDA's own bulk substances guidance page confirms which peptides currently qualify, and AOD-9604 isn't among the compounds cleared there ^[10]. Compounding of AOD-9604 under 21 U.S.C. 353a isn't the legal pathway that's currently open for it ^[11]. Practically: buying it as a research chemical for non-human use sits in a gray zone that a lot of vendors occupy. Buying it with the expectation of injecting it into yourself for fat loss is a different thing, and it's the part regulators care about.

Where can you actually buy AOD-9604 right now?

Three channels exist, and they're not equal. Research chemical vendors sell it as a lab compound, no prescription, shipped as lyophilized powder. This is the overwhelming majority of what shows up when you search 'aod 9604 for sale' or 'buy aod9604.' Quality control varies enormously between these sellers, and there's no regulatory body checking that the vial contains what the label claims. Compounding pharmacies working with a prescriber are a second channel, though because AOD-9604 isn't on the 503A or 503B bulks lists, a pharmacy offering it under a medical framework is operating outside the clearly sanctioned pathway ^[8][9]. Provider-reviewed peptide programs are a third option, where a clinician reviews your case before anything ships. AOD-9604 Co works with a fulfilling pharmacy partner under that reviewed model, which at minimum means a human is looking at your health history rather than a checkout page taking your card number. If sourcing quality is your main worry, our best place to buy AOD-9604 guide breaks down what separates a defensible vendor from a shady one.

How much does AOD-9604 cost, and is the price a red flag either way?

Prices for AOD-9604 sold as a research peptide commonly run from roughly $30 to $90 for a small vial (typically 2mg or 5mg), depending on the vendor, purity claims, and whether third-party testing is included. That range reflects general research-peptide market pricing rather than one specific published source, and it moves constantly. A rock-bottom price is not a bargain if there's no certificate of analysis behind it. A high price is not proof of quality either. What actually tells you something is whether the vendor publishes third-party mass spectrometry or HPLC testing for the specific batch you're buying, more than a generic 'we test everything' claim on the homepage. Ask for a batch-specific certificate of analysis before you pay. If a vendor can't produce one, that's your answer.

How is AOD-9604 dosed and injected, if someone chooses to use it?

Research protocols for AOD-9604 commonly describe subcutaneous injection, once daily, typically discussed in the 300 mcg to 500 mcg range in the peptide research community. Nobody should mistake community dosing chatter for a validated clinical protocol, because AOD-9604 doesn't have an FDA-approved label with dosing instructions, and the human obesity trials that tested it did not produce a clear efficacy signal to anchor a dose recommendation to ^[1]. Reconstitution matters a lot with lyophilized peptides. Get the water volume, storage temperature, and stability window wrong, and you're injecting something degraded regardless of what the original vial contained. Our how to reconstitute AOD-9604 guide walks through that process step by step, and AOD-9604 how to inject covers injection technique and site rotation. Timing questions come up constantly too, usually about whether to inject fasted, before cardio, or before bed. See when to take AOD-9604 peptide for what the fragment's proposed mechanism would actually predict, versus what's just gym folklore.

Will AOD-9604 show up on a drug test or get you flagged in sport?

This is one place AOD-9604 actually has decent published data behind it, separate from the murky efficacy question. A 2013 study in Drug Testing and Analysis tested whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test anti-doping labs use to detect growth hormone doping, and found it does not influence that assay ^[12]. That's a narrow, specific finding: AOD-9604 doesn't trigger a false signal on that one hGH test. It doesn't mean AOD-9604 is undetectable generally, or that it's permitted in tested sport. Separate analytical work has developed direct urine injection and ion mobility mass spectrometry methods specifically to screen for peptides under 2 kDa, a size class that includes fragments like AOD-9604, precisely because standard panels can miss small peptides ^[13]. Broader reviews of anti-doping detection methods for emerging peptide therapeutics describe an active, evolving effort to close these gaps ^[14][15]. If you compete under any tested federation, assume detection methods are advancing faster than any 2013 finding suggests, and don't treat 'doesn't affect one immunoassay' as a green light.

What does the safety data on AOD-9604 actually show?

There isn't much dedicated long-term human safety data on AOD-9604 specifically, which is a gap, not a clean bill of health. It's referenced in broader recent literature covering peptide use in orthopaedics and athletic performance contexts, including a 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews on therapeutic peptides in orthopaedic applications ^[16], and a 2026 Sports Medicine review on safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance ^[17]. Both of those papers place AOD-9604 within a wider unapproved-peptide landscape rather than reporting dedicated long-term safety trials for it alone. That's worth sitting with: the most recent literature discussing AOD-9604 is grouping it with other compounds that lack FDA review, not singling it out as a peptide with an established safety record. Because it's unregulated as a consumer product, batch-to-batch purity, endotoxin levels, and sterility depend entirely on whoever manufactured your specific vial. That's a bigger practical safety concern for most buyers than any theoretical hormone-related side effect.

How does AOD-9604 compare to other fat-loss options with better evidence?

AOD-9604 sits at the weak end of the evidence spectrum compared to both approved obesity drugs and even other peptides in the same 'growth hormone fragment' family.

Tesamorelin's approval means it cleared an FDA efficacy and safety bar that AOD-9604 never has. GLP-1 drugs have the deepest trial base of any obesity pharmacotherapy class right now. Neither of those categories is what most 'aod 9604 buy' searches are actually shopping for, since AOD-9604 is marketed and priced as a cheap research peptide, not a clinical-grade drug, but the honest comparison still matters before you spend money on the promise alone. For the specific mechanistic and trial-design comparison against tesamorelin, our AOD 9604 vs tesamorelin page goes deeper than this table can.

So is buying AOD-9604 for fat loss worth it?

Straight answer: the trial record doesn't support strong expectations. AOD-9604 reached human obesity trials, and the reported weight loss did not clearly beat placebo across that program. That's not a marketing spin problem, it's the core data problem, and no amount of vendor testing or clean sourcing fixes a compound that didn't separate from placebo in the trials that mattered. If you're going to buy it anyway, at minimum: get batch-specific third-party testing, understand you're buying a research chemical with no FDA-approved label, and go in with realistic expectations shaped by the actual trial outcomes rather than forum anecdotes. If you want a provider involved rather than a straight checkout purchase, AOD-9604 Co works with a fulfilling pharmacy partner under a provider-reviewed model, meaning a clinician looks at your case before anything ships. That doesn't change the underlying trial data. It changes who's checking your history before you inject something.

Frequently asked questions

Is AOD-9604 FDA approved for weight loss?

No. AOD-9604 has no listing in the FDA's Drugs@FDA database, meaning it is not approved for weight loss or any other indication in the United States. It's sold as a research chemical, not a regulated pharmaceutical, which is a key reason to be cautious before buying it.

Where can I buy AOD-9604 peptide?

It's sold by research chemical vendors online (no prescription required), by some compounding pharmacies working outside FDA's approved bulk substances lists, and through provider-reviewed peptide programs that involve a clinician before fulfillment. Quality and legitimacy vary enormously between these channels; batch-specific third-party testing is the main thing to check.

How much does AOD-9604 cost per vial?

Research-market prices commonly run roughly $30 to $90 for a small vial (2mg to 5mg), though pricing shifts constantly and varies by vendor and testing claims. Price alone doesn't indicate quality; ask for a batch-specific certificate of analysis regardless of what you pay.

Does AOD-9604 actually cause fat loss in humans?

AOD-9604 went through human obesity trials, and while some weight loss was reported in treated groups, it did not separate convincingly from placebo across the program ^[1]. It reached clinical testing but never achieved FDA approval for obesity or weight management.

Will AOD-9604 fail a drug test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not influence the WADA hGH isoform immunoassay, the standard test for growth hormone doping ^[12]. That's a narrow finding about one assay, not proof the compound is undetectable or permitted under any anti-doping code.

Is it legal to buy AOD-9604 in the US?

It's typically sold labeled 'research use only,' a legal category that depends heavily on how it's actually marketed and used, per FDA's intended-use standard under 21 CFR 201.128. It is not on either FDA bulk drug substances list (503A or 503B) that permits compounding pharmacies to prepare it for patient use.

What's the difference between AOD-9604 and tesamorelin?

Tesamorelin is FDA-approved for HIV-associated lipodystrophy with trial data supporting that approval. AOD-9604 has no FDA approval for any use, and its obesity trials did not show weight loss that clearly beat placebo. See our AOD 9604 vs tesamorelin comparison for the full trial-design breakdown.

How is AOD-9604 typically dosed?

Research community protocols commonly describe subcutaneous injection once daily, often discussed in the 300 to 500 mcg range, but there is no FDA-approved label or validated clinical dosing protocol behind these numbers. They come from research chemical community usage, not regulatory guidance.

Can a compounding pharmacy legally make AOD-9604?

AOD-9604 is not on the FDA's 503A bulks list (21 CFR 216.23) or 503B bulks list (21 CFR 216.24), the lists that authorize compounding pharmacies and outsourcing facilities to prepare specific bulk substances for patients. Compounding it currently falls outside that clearly sanctioned regulatory pathway.

Is AOD-9604 safe long-term?

There's limited dedicated long-term human safety data specific to AOD-9604. Recent 2026 reviews in orthopaedic and sports medicine journals discuss it within a broader category of unapproved peptide therapies rather than reporting long-term safety trials focused on it alone, which is itself a gap worth taking seriously.

Why did AOD-9604 stop progressing after Phase II trials?

Published trial-tracking records show AOD-9604 moving through Phase II obesity trials around 2003 to 2005, but it never reached FDA approval. The core reason documented in the literature is that weight loss in treated groups did not separate convincingly from placebo, which is typically what stalls an obesity drug candidate's progression.

What should I check before buying AOD-9604 from a vendor?

Ask for a batch-specific third-party certificate of analysis (mass spectrometry or HPLC), not a generic homepage claim. Check whether the vendor discloses sourcing and storage conditions, and be skeptical of fat-loss claims that outpace what the actual human obesity trials showed.

Does AOD-9604 have the same side effects as full-length HGH?

The original rationale for AOD-9604 was to isolate hGH's fat-metabolizing fragment while avoiding growth-promoting and blood-sugar effects tied to full-length hGH ^[1]. Whether that separation holds up cleanly in practice isn't established by strong long-term human safety data, so don't assume it's risk-free just because it's a fragment.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004), PMID 15134286: AOD-9604's proposed fat-metabolizing mechanism and status as an anti-obesity drug candidate; weight loss in trials did not clearly separate from placebo
2. PubMed, Current Opinion in Investigational Drugs (2006), PMID 16625817: AOD-9604 was tracked among a broader field of obesity drug candidates in clinical development as of 2006
3. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003), PMID 14685303: Trial pipeline tracking recorded AOD-9604 in clinical development stages in 2003
4. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003), PMID 14571286: Additional 2003 trial-gateway tracking of AOD-9604 among compounds in clinical pipelines
5. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005), PMID 15834452: 2005 trial pipeline tracking shows AOD-9604 continuing through clinical stages without reaching approval
6. FDA, Drugs@FDA database: No AOD-9604 product is listed as an FDA-approved drug in the Drugs@FDA database
7. eCFR, 21 CFR 201.128: A product's intended use for regulatory purposes is determined by labeling, advertising, and representations, more than disclaimers
8. eCFR, 21 CFR 216.23 (503A Bulks List): AOD-9604 is not on the FDA's 503A bulk drug substances list authorizing compounding pharmacies to use it
9. eCFR, 21 CFR 216.24 (503B Bulks List): AOD-9604 is not on the FDA's 503B bulk drug substances list authorizing outsourcing facility compounding
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA maintains the current list of bulk substances cleared for 503A compounding, which does not include AOD-9604
11. Cornell Law, 21 U.S.C. 353a (pharmacy compounding): Legal framework governing which bulk substances pharmacies may compound for patients
12. PubMed, Drug Testing and Analysis (2013), PMID 24124033: AOD-9604 does not influence the WADA hGH isoform immunoassay used in anti-doping testing
13. PubMed, Journal of Separation Science (2016), PMID 26578461: Analytical methods using direct urine injection and ion mobility mass spectrometry were developed to screen peptides under 2 kDa, a class including fragments like AOD-9604
14. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014), PMID 24906629: Analytical detection approaches for emerging peptide therapeutics and non-approved drugs in doping controls are actively evolving
15. PubMed, Expert Review of Proteomics (2014), PMID 25382550: Review of current status and future directions for detecting peptidic drugs and analogs in sports doping
16. PubMed, JAAOS Global Research & Reviews (2026), PMID 41490200: AOD-9604 is discussed within a broader review of therapeutic peptides in orthopaedic applications, challenges, and future directions
17. PubMed, Sports Medicine (2026), PMID 41966639: AOD-9604 is grouped among approved and unapproved peptide therapies reviewed for safety and efficacy in musculoskeletal and athletic performance contexts